Radius Health Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Radius Health (RDUS) PT Lifted to $56 at Jefferies; Potentially Early Efficacy Data for RAD1901 at ASCO
March 11, 2015 7:35 AM EDTJefferies analyst Eun K. Yang reiterated a Buy rating and lifted the price target on Radius Health (NASDAQ: RDUS) to $56.00 (from $45.00) following in-line Q4 results but potentially early efficacy data for RAD1901 at ASCO.
Yang commented, "With positive, clean Ph3 data for... More
Radius Health (RDUS) Reports Narrower Q4 Loss Than Expected
March 10, 2015 8:51 AM EDTRadius Health (NASDAQ: RDUS) reported Q4 EPS of ($0.55), $0.08 better than the analyst estimate of ($0.63).
For earnings history and earnings-related data on Radius Health (RDUS) click here.
... More